Gratus Capital’s Immunic IMUX Stock Holding History

Gratus Capital’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$2.34M	Buy	210,966 +5,685	+3%	+$70.6K	0.09%	135
2024 Q1	$2.71M	Buy	205,281 +11,136	+6%	+$145K	0.12%	116
2023 Q4	$2.91M	Buy	194,145 +25,499	+15%	+$312K	0.16%	104
2023 Q3	$2.48M	Buy	168,646 +767	+0.5%	+$14.7K	0.17%	100
2023 Q2	$4.21M	Buy	167,879 +2,338	+1%	+$39.2K	0.29%	79
2023 Q1	$2.47M	Sell	165,541 -1,288	-0.8%	-$23.9K	0.19%	85
2022 Q4	$2.34M	Buy	166,829 +91,510	+121%	+$2.5M	0.19%	83
2022 Q3	$2.38M	Buy	+75,319	New	+$3.15M	0.25%	77

Other funds holding IMUX

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Gratus Capital's IMUX Position: Q2 2024 in Review

Gratus Capital increased its Immunic (IMUX) stake by 2.8% in Q2 2024, buying an estimated $70.6K and bringing the position to 210,966 shares worth $2.34M. The position accounts for 0.09% of the portfolio, ranked #135.

Gratus Capital first reported a position in IMUX in Q3 2022 and has held it in 8 quarters since. The position peaked at $4.21M in Q2 2023. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2024.

Gratus Capital held 210,966 shares of Immunic worth $2.34M as of Q2 2024.
Gratus Capital bought 5,685 Immunic shares in Q2 2024, an estimated $70.6K.
Immunic made up 0.09% of Gratus Capital's portfolio in Q2 2024, its #135 holding.
Gratus Capital first reported a position in Immunic in Q3 2022 and has held it in 8 quarters since.
Gratus Capital's Immunic position peaked at $4.21M in Q2 2023.
55 funds tracked by Wall St. Rank held Immunic as of Q2 2024.

Based on Gratus Capital's 13F filing for Q2 2024, filed 25 Jul 2024.